{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:37:23Z","timestamp":1773790643480,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Radiotherapy (RT) causes an inflammatory reaction of the tissue which leads to fibrosis and reduced functioning of the pelvic organs. Few studies have shown significant relationships between side effects and RT in uterine tumors. Here, the urological, lymphedema, pelvic pain and gastrointestinal (GI) symptoms were studied before and after RT in patients with primary uterine tumors using the EORTC QLQ-EN24, specifically designed for uterine cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study comprised patients with primary uterine tumors who received pelvic radiotherapy (RT). A total of 43 patients were included from May 2014 to February 2019. Patients completed the questionnaires for global health status and functioning before the start of RT and at 3 and 12\u00a0months after RT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found a significant worsening of the urological symptoms 3\u00a0months after RT which persisted up to 12\u00a0months after RT compared to baseline values prior to start of RT (<jats:italic>p<\/jats:italic>\u2009=\u20090.007). An exacerbation of the urinary symptoms was seen in patients with vaginal brachytherapy\/boost compared to patients with pelvic RT at 12\u00a0months after RT (<jats:italic>p<\/jats:italic>\u2009=\u20090.053). The severity of lymphedema symptoms increased from RT start to 12\u00a0months after RT (<jats:italic>p<\/jats:italic>\u2009=\u20090.019) and the pelvic pain were higher at 3\u00a0months after RT compared to before RT (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Also, the level of GI symptoms was significantly higher 12\u00a0months after RT compared to the RT start (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The urologic, lymphedema, pelvic pain and GI symptoms all increase after RT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02576-y","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T18:03:28Z","timestamp":1615226608000},"page":"1752-1760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Urologic, lymphedema, pelvic pain and gastrointestinal symptoms increase after radiotherapy in patients with primary uterine tumors: a prospective longitudinal Swedish cohort study"],"prefix":"10.1007","volume":"23","author":[{"given":"A.","family":"Holmqvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mikivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Redelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Odelram Wir\u00e9en","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Uppugunduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"3","key":"2576_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ygyno.2004.08.019","volume":"95","author":"WT Creasman","year":"2004","unstructured":"Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95(3):593\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2004.08.019.","journal-title":"Gynecol Oncol"},{"issue":"9213","key":"2576_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/s0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213):1404\u201311. https:\/\/doi.org\/10.1016\/s0140-6736(00)02139-5.","journal-title":"Lancet"},{"issue":"11","key":"2576_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S1470-2045(07)70341-8","volume":"8","author":"J Andreyev","year":"2007","unstructured":"Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8(11):1007\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(07)70341-8.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2576_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.clon.2012.04.001","volume":"24","author":"CB Westbury","year":"2012","unstructured":"Westbury CB, Yarnold JR. Radiation fibrosis\u2013current clinical and therapeutic perspectives. Clin Oncol. 2012;24(10):657\u201372. https:\/\/doi.org\/10.1016\/j.clon.2012.04.001.","journal-title":"Clin Oncol"},{"issue":"1","key":"2576_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/flgastro-2012-100218","volume":"4","author":"AC Muls","year":"2013","unstructured":"Muls AC, Watson L, Shaw C, Andreyev HJN. Managing gastrointestinal symptoms after cancer treatment: a practical approach for gastroenterologists. Frontline Gastroenterol. 2013;4(1):57\u201368. https:\/\/doi.org\/10.1136\/flgastro-2012-100218.","journal-title":"Frontline Gastroenterol"},{"issue":"21","key":"2576_CR6","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","volume":"27","author":"RA Nout","year":"2009","unstructured":"Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27(21):3547\u201356. https:\/\/doi.org\/10.1200\/JCO.2008.20.2424.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2576_CR7","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S1470-2045(16)30120-6","volume":"17","author":"SM de Boer","year":"2016","unstructured":"de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(8):1114\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)30120-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2576_CR8","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ejca.2011.11.014","volume":"48","author":"RA Nout","year":"2012","unstructured":"Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised post operative radiation therapy in endometrial cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012;48(11):1638\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.014.","journal-title":"Eur J Cancer"},{"issue":"2 Pt 1","key":"2576_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/AOG.0000000000000372","volume":"124","author":"KJ Yost","year":"2014","unstructured":"Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA, McGree ME, et al. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol. 2014;124(2 Pt 1):307\u201315. https:\/\/doi.org\/10.1097\/AOG.0000000000000372.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2576_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2014.11.006","volume":"136","author":"VL Beesley","year":"2015","unstructured":"Beesley VL, Rowlands IJ, Hayes SC, Janda M, O\u2019Rourke P, Marquart L, et al. Incidence, risk factors and estimates of a woman\u2019s risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncol. 2015;136(1):87\u201393. https:\/\/doi.org\/10.1016\/j.ygyno.2014.11.006.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2576_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ygyno.2010.06.018","volume":"119","author":"Y Todo","year":"2010","unstructured":"Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol. 2010;119(1):60\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2010.06.018.","journal-title":"Gynecol Oncol"},{"issue":"9658","key":"2576_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","volume":"373","author":"Group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK","year":"2009","unstructured":"Group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(08)61766-3.","journal-title":"Lancet"},{"issue":"3","key":"2576_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ygyno.2006.06.038","volume":"103","author":"H Ikushima","year":"2006","unstructured":"Ikushima H, Osaki K, Furutani S, Yamashita K, Kishida Y, Kudoh T, et al. Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures. Gynecol Oncol. 2006;103(3):1100\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2006.06.038.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2576_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2011.315","volume":"105","author":"H Lind","year":"2011","unstructured":"Lind H, Waldenstrom AC, Dunberger G, al-Abany M, Alevronta E, Johansson KA, , et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer. 2011;105(6):737\u201345. https:\/\/doi.org\/10.1038\/bjc.2011.315.","journal-title":"Br J Cancer"},{"issue":"2","key":"2576_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11764-011-0172-z","volume":"5","author":"I Vistad","year":"2011","unstructured":"Vistad I, Cvancarova M, Kristensen GB, Fossa SD. A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv. 2011;5(2):208\u201316. https:\/\/doi.org\/10.1007\/s11764-011-0172-z.","journal-title":"J Cancer Surviv"},{"issue":"3","key":"2576_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295\u2013309. https:\/\/doi.org\/10.1016\/S1470-2045(18)30079-2.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2576_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","volume":"20","author":"SM de Boer","year":"2019","unstructured":"de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(19)30395-X.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2576_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ijrobp.2015.08.023","volume":"93","author":"SM de Boer","year":"2015","unstructured":"de Boer SM, Nout RA, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial. Int J Radiat Oncol Biol Phys. 2015;93(4):797\u2013809. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2576_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2576_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2010.08.014","volume":"47","author":"E Greimel","year":"2011","unstructured":"Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB, et al. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer. 2011;47(2):183\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2010.08.014.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2576_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89\u201396. https:\/\/doi.org\/10.1200\/JCO.2010.28.0107.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2576_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11934-018-0848-2","volume":"19","author":"LS Leddy","year":"2018","unstructured":"Leddy LS. Management of lower urinary tract symptoms after pelvic radiation in females. Curr Urol Rep. 2018;19(12):106. https:\/\/doi.org\/10.1007\/s11934-018-0848-2.","journal-title":"Curr Urol Rep"},{"issue":"13","key":"2576_CR23","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s40265-015-0443-5","volume":"75","author":"X Liem","year":"2015","unstructured":"Liem X, Saad F, Delouya G. A practical approach to the management of radiation-induced hemorrhagic cystitis. Drugs. 2015;75(13):1471\u201382. https:\/\/doi.org\/10.1007\/s40265-015-0443-5.","journal-title":"Drugs"},{"issue":"5","key":"2576_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.clgc.2016.01.016","volume":"14","author":"M Gacci","year":"2016","unstructured":"Gacci M, Saleh O, Giannessi C, Chini T, Della Camera PA, Detti B, et al. Bladder instillation therapy with hyaluronic acid and chondroitin sulfate improves symptoms of postradiation cystitis: prospective pilot study. Clin Genitourin Cancer. 2016;14(5):444\u20139. https:\/\/doi.org\/10.1016\/j.clgc.2016.01.016.","journal-title":"Clin Genitourin Cancer"},{"issue":"21","key":"2576_CR25","doi-asserted-by":"publisher","first-page":"7562","DOI":"10.26355\/eurrev_201811_16298","volume":"22","author":"D Cosentino","year":"2018","unstructured":"Cosentino D, Piro F. Hyaluronic acid for treatment of the radiation therapy side effects: a systematic review. Eur Rev Med Pharmacol Sci. 2018;22(21):7562\u201372. https:\/\/doi.org\/10.26355\/eurrev_201811_16298.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T11:18:11Z","timestamp":1627125491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02576-y","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest or no funding sources that might generate a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the regional ethical committee in Link\u00f6ping, Sweden in accordance with the declaration of Helsingki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients had signed a written informed consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}